Q-omics provides the consensus-scored MYO6 profile across patient tissues and cancer cell-line models. MYO6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MYO6 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, MYO6 RNA expression shows 20,372 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where MYO6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYO6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYO6 survival associations across molecular data types. MYO6 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYO6 RNA expression–survival associations across cancer types. High MYO6 expression shows unfavorable associations in MESO, CESC and ESCA, but favorable associations in KIRC, LUAD and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MYO6 RNA expression.
This table summarizes MYO6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MYO6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYO6 shows lower tumor expression in KICH and KIRC and higher tumor expression in STAD, BLCA, THCA and UCEC. The KICH box plot shows higher MYO6 RNA expression in normal versus tumor tissue (log2 FC = −1.549, t-test p < 0.001).
This table shows molecular features associated with MYO6 in patient tissues and cancer cell lines. In patient samples, MYO6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MYO6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
